Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration

THOUSAND OAKS, Calif. and PRINCETON, N.J., Aug. 2, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) today announced a global agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical investigational cancer immunotherapy… http://www.prnewswire.com/news-releases/amgen-and-advaxis-enter-global-cancer-immunotherapies-collaboration-300307287.html